Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on serious skeletal and cardiac muscle diseases. It develops oral small-molecule candidates designed to protect and preserve muscle function, including programs aimed at muscular dystrophies such as Becker and Duchenne and at cardiac muscle conditions. Its approach emphasizes muscle biology and a muscle-focused discovery platform rather than broad multi-indication portfolios. With limited commercial sales to date, value is driven by R&D progress and clinical development.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -40.8 | — |
| Q2 2025 | 0 | — | -36.1 | — |
| Q3 2025 | 0 | — | -40.7 | — |
| Q4 2025 | 0 | — | -50.2 | — |
| Q1 2026 | 0 | — | -49 | — |
| Q2 2026 | 0 | — | -57.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Enphase Energy, Inc. (ENPH), CorVel Corporation (CRVL), Cavco Industries, Inc. (CVCO), Cathay General Bancorp (CATY), USA Rare Earth, Inc. (USAR), Dianthus Therapeutics, Inc. (DNTH)